Cargando…
Validation of a transparent decision model to rate drug interactions
BACKGROUND: Multiple databases provide ratings of drug-drug interactions. The ratings are often based on different criteria and lack background information on the decision making process. User acceptance of rating systems could be improved by providing a transparent decision path for each category....
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598205/ https://www.ncbi.nlm.nih.gov/pubmed/22950884 http://dx.doi.org/10.1186/2050-6511-13-7 |
_version_ | 1782262737404952576 |
---|---|
author | Far, Elmira Curkovic, Ivanka Byrne, Kelly Roos, Malgorzata Egloff, Isabelle Dietrich, Michael Kirch, Wilhelm Kullak-Ublick, Gerd-A Egbring, Marco |
author_facet | Far, Elmira Curkovic, Ivanka Byrne, Kelly Roos, Malgorzata Egloff, Isabelle Dietrich, Michael Kirch, Wilhelm Kullak-Ublick, Gerd-A Egbring, Marco |
author_sort | Far, Elmira |
collection | PubMed |
description | BACKGROUND: Multiple databases provide ratings of drug-drug interactions. The ratings are often based on different criteria and lack background information on the decision making process. User acceptance of rating systems could be improved by providing a transparent decision path for each category. METHODS: We rated 200 randomly selected potential drug-drug interactions by a transparent decision model developed by our team. The cases were generated from ward round observations and physicians’ queries from an outpatient setting. We compared our ratings to those assigned by a senior clinical pharmacologist and by a standard interaction database, and thus validated the model. RESULTS: The decision model rated consistently with the standard database and the pharmacologist in 94 and 156 cases, respectively. In two cases the model decision required correction. Following removal of systematic model construction differences, the DM was fully consistent with other rating systems. CONCLUSION: The decision model reproducibly rates interactions and elucidates systematic differences. We propose to supply validated decision paths alongside the interaction rating to improve comprehensibility and to enable physicians to interpret the ratings in a clinical context. |
format | Online Article Text |
id | pubmed-3598205 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35982052013-03-16 Validation of a transparent decision model to rate drug interactions Far, Elmira Curkovic, Ivanka Byrne, Kelly Roos, Malgorzata Egloff, Isabelle Dietrich, Michael Kirch, Wilhelm Kullak-Ublick, Gerd-A Egbring, Marco BMC Pharmacol Toxicol Research Article BACKGROUND: Multiple databases provide ratings of drug-drug interactions. The ratings are often based on different criteria and lack background information on the decision making process. User acceptance of rating systems could be improved by providing a transparent decision path for each category. METHODS: We rated 200 randomly selected potential drug-drug interactions by a transparent decision model developed by our team. The cases were generated from ward round observations and physicians’ queries from an outpatient setting. We compared our ratings to those assigned by a senior clinical pharmacologist and by a standard interaction database, and thus validated the model. RESULTS: The decision model rated consistently with the standard database and the pharmacologist in 94 and 156 cases, respectively. In two cases the model decision required correction. Following removal of systematic model construction differences, the DM was fully consistent with other rating systems. CONCLUSION: The decision model reproducibly rates interactions and elucidates systematic differences. We propose to supply validated decision paths alongside the interaction rating to improve comprehensibility and to enable physicians to interpret the ratings in a clinical context. BioMed Central 2012-08-20 /pmc/articles/PMC3598205/ /pubmed/22950884 http://dx.doi.org/10.1186/2050-6511-13-7 Text en Copyright ©2012 Far et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Far, Elmira Curkovic, Ivanka Byrne, Kelly Roos, Malgorzata Egloff, Isabelle Dietrich, Michael Kirch, Wilhelm Kullak-Ublick, Gerd-A Egbring, Marco Validation of a transparent decision model to rate drug interactions |
title | Validation of a transparent decision model to rate drug interactions |
title_full | Validation of a transparent decision model to rate drug interactions |
title_fullStr | Validation of a transparent decision model to rate drug interactions |
title_full_unstemmed | Validation of a transparent decision model to rate drug interactions |
title_short | Validation of a transparent decision model to rate drug interactions |
title_sort | validation of a transparent decision model to rate drug interactions |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3598205/ https://www.ncbi.nlm.nih.gov/pubmed/22950884 http://dx.doi.org/10.1186/2050-6511-13-7 |
work_keys_str_mv | AT farelmira validationofatransparentdecisionmodeltoratedruginteractions AT curkovicivanka validationofatransparentdecisionmodeltoratedruginteractions AT byrnekelly validationofatransparentdecisionmodeltoratedruginteractions AT roosmalgorzata validationofatransparentdecisionmodeltoratedruginteractions AT egloffisabelle validationofatransparentdecisionmodeltoratedruginteractions AT dietrichmichael validationofatransparentdecisionmodeltoratedruginteractions AT kirchwilhelm validationofatransparentdecisionmodeltoratedruginteractions AT kullakublickgerda validationofatransparentdecisionmodeltoratedruginteractions AT egbringmarco validationofatransparentdecisionmodeltoratedruginteractions |